Home » Stocks » Dynavax Technologies

Dynavax Technologies Corporation (DVAX)

Stock Price: $7.68 USD -1.15 (-12.98%)
Updated Aug 7, 2020 3:01 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 707.51M
Revenue (ttm) 34.73M
Net Income (ttm) -125.52M
Shares Out 108.80M
EPS (ttm) -1.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $7.68
Previous Close $8.82
Change ($) -1.15
Change (%) -12.98%
Day's Open 8.15
Day's Range 7.08 - 8.23
Day's Volume 7,200,864
52-Week Range 1.80 - 12.44

More Stats

Market Cap 707.51M
Enterprise Value 794.32M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 108.80M
Float 76.59M
EPS (basic) -1.71
EPS (diluted) -1.61
FCF / Share -1.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15.24M
Short Ratio 2.08
Short % of Float 16.67%
Beta 1.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 20.37
PB Ratio 82.44
Revenue 34.73M
Operating Income -116.30M
Net Income -125.52M
Free Cash Flow -129.09M
Net Cash -86.81M
Net Cash / Share -0.94
Gross Margin -107.35%
Operating Margin -334.85%
Profit Margin -319.10%
FCF Margin -371.67%
ROA -19.59%
ROE -390.20%
ROIC -26.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(108.47% upside)
Current: $7.68
Target: 16.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth329.6%2407.03%-97.04%172.67%-63.29%-1.95%15.82%-55.06%-9.75%-
Gross Profit15.83-13.60-0.8711.044.0511.0311.259.7121.6123.95
Operating Income-135-153-96.01-111-105-91.31-66.49-67.60-47.58-47.59
Net Income-153-159-95.15-112-107-90.72-66.72-69.95-48.60-57.31
Shares Outstanding72.0262.3652.6138.5132.8826.2919.6317.0512.518.25
Earnings Per Share-2.16-2.55-1.81-2.92-3.25-3.45-3.83-4.10-3.90-6.90
Operating Cash Flow-121-131-77.52-107-92.56-73.74-58.67-43.81-47.12-51.37
Capital Expenditures-22.40-4.19-0.67-7.76-6.97-1.67-1.63-2.93-1.14-0.42
Free Cash Flow-144-135-78.19-115-99.53-75.41-60.30-46.74-48.26-51.79
Cash & Equivalents15114619282.0219712319012611572.81
Total Debt216101---9.56--12.8110.94
Net Cash / Debt-65.1845.2819282.0219711419012610261.87
Book Value8.2963.0720089.2018710018611599.8852.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dynavax Technologies Corporation
Country United States
Employees 231
CEO Ryan Spencer

Stock Information

Ticker Symbol DVAX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DVAX
IPO Date February 19, 2004


Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.